Expert Opinion on Emerging Drugs

Papers
(The TQCC of Expert Opinion on Emerging Drugs is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity59
Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials35
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials22
Emerging synthetic drugs for the treatment of liver cirrhosis17
Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials15
Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma14
Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa14
Emerging therapeutics in Huntington’s disease14
Emerging drugs for the treatment of adult MOG-IgG-associated diseases12
Emerging therapies for dry eye disease12
Designing phase II clinical trials in Friedreich ataxia11
Emerging topical drugs for the treatment of rosacea10
Emerging drugs for the treatment of myasthenia gravis10
Emerging drugs for the treatment of alopecia areata10
Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials9
Emerging antiviral therapies and drugs for the treatment of influenza9
Emerging drugs for the acute treatment of relapses in adult neuromyelitis optica spectrum disorder patients8
Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma8
Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia7
Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials7
Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials7
Emerging biological therapies for the treatment of age-related macular degeneration7
Emerging drugs for the treatment of diabetic nephropathy6
Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria6
Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials6
Emerging drugs for the treatment of postsurgical pain6
Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials5
Emerging drugs for the treatment of cutaneous T-cell lymphoma5
Emerging biological drugs for the treatment of gastroesophageal adenocarcinoma5
Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials5
Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer5
Emerging drugs for the treatment of basal cell carcinoma5
A review of emerging factor XI inhibitors5
Emerging drugs for dementia with Lewy Bodies: a review of Phase II & III trials5
Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention5
A review of phase II and III drugs for the treatment and management of endometriosis5
0.03338098526001